Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Mauna Kea Technologies SA operates as a medical device enterprise, producing and distributing its offerings throughout Europe and worldwide. Its product line serves various medical specialties such as gastroenterology, pulmonology, and urology. Central to its portfolio is Cellvizio, an in vivo cellular imaging platform that delivers real-time data. This innovative system assists medical practitioners in tracking disease evolution, evaluating immediate physiological responses, delineating ambiguous tissue areas, and providing guidance during surgical procedures. Founded in 2000, the company's headquarters are situated in Paris, France.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/E